The case centers on the January 2023 merger of Orthofix Medical Inc., a Texas-based spine and orthopedics company, and SeaSpine Holdings Corp., a California-based medical technology company. About six months after the merger closed, Orthofix's board received a complaint from Kevin Kenny, identified in the complaint as then-President of Orthofix Global Spine, detailing multiple workplace issues and inappropriate conduct by the three executives who had come over from SeaSpine — Keith Valentine, John Bostjancic, and Patrick Keran — to serve as CEO, CFO, and CLO of the combined company. An internal investigation by outside counsel from DLA Piper and Latham & Watkins followed. On September 12, 2023, Orthofix announced the unanimous decision by the board's independent directors to terminate the three executives for cause. The next day, Orthofix's stock fell $5.62 per share, or over 30%, closing at $13.01 on unusually heavy volume and wiping out $206.5 million in market capitalization.
The securities class action, In re Orthofix Medical, Inc. Securities Litigation, No. 2:24-CV-00690-JRG, alleges that the merger prospectus and related documents contained material misrepresentations. The most consequential surviving allegation involves a representation and warranty in the merger agreement — included as an appendix to the prospectus — in which SeaSpine stated that within the past four years it had not entered into any settlement agreement pertaining to misconduct allegations. That statement was false: SeaSpine had settled the Johnson Action, a discrimination class action brought by 276 current and former female employees, with a court-approved settlement on July 26, 2021, requiring SeaSpine to pay $919,500.87 in settlement funds.
Judge Rodney Gilstrap held that the non-reliance disclaimer in the prospectus — which warned shareholders not to rely on the representations and warranties as characterizations of actual facts — does not create a per se bar to liability. Reading the statement in its full context, the court held that the materiality of the warranty is not appropriate for resolution at the motion to dismiss stage, because a reasonable jury could find the warranty material to investors, particularly given that the prospectus also encouraged shareholders to read the merger agreement carefully and in its entirety. The court also rejected defendants' argument that Federal Rule of Evidence 408 barred plaintiffs from using the Johnson Action settlement to demonstrate a material misstatement, holding that Rule 408 applies to proving liability for the settled claim itself, not to demonstrating falsity of a disclosure in a securities case.
By contrast, the court dismissed Counts I and II under Section 10(b) and Rule 10b-5, and the related Section 20(a) control person claims, because plaintiffs failed to plead loss causation. The court held that plaintiffs' own allegations — and the analyst commentary they quoted — pointed overwhelmingly to the sudden departure of the Terminated Executives as the cause of the stock drop, not to any corrective disclosure about the Johnson Action or the merger agreement warranty. The September 12 and 14, 2023 disclosures addressed only the for-cause terminations, not the underlying merger misrepresentation, and the court held that plaintiffs would have suffered the same harm regardless of whether those disclosures had been made.
The court dismissed Statement Types 1, 3, 4, 5, and 6 — covering statements about complementary corporate cultures, the individual merit of post-merger leadership, and commitments to diversity, ethics, and compliance — as immaterial corporate puffery under Fifth Circuit precedent, and denied leave to amend those claims as futile. Leave to amend was granted only on loss causation; plaintiffs have 30 days from the March 9, 2026 order to file a Second Amended Complaint addressing that deficiency. The Securities Act claims under Sections 11, 12(a)(2), and 15 survive in full.